Up to 18 Argenta scientists will work on the Novartis programme, which centres on the search for new diabetes therapies
Argenta Discovery, a contract drug discovery and respiratory drug development company, has entered into two-year drug discovery collaboration with Novartis.
Argenta's medicinal chemistry teams will collaborate with Novartis's scientists in the search for new disease therapies.
The deal also provides Novartis with access to Argenta's other scientific disciplines.
Commenting on the agreement, Chris Ashton, Argenta's CEO, said, "We are delighted that one of the world's leading pharmaceutical companies has chosen to work with Argenta on this important programme.
"This new agreement, which is the first since our recent merger with Etiologics, underlines Argenta's excellence in collaborative drug discovery.
"The deal involves a substantial commitment from Novartis and provides an excellent conclusion to a successful year of robust growth for our contract drug discovery business".
Up to 18 Argenta scientists will work on the Novartis programme, which centres on the search for new diabetes therapies.
